[Correspondence] SunRISe-4 perioperative safety and TURBT stratification

We read with great interest the interim analysis of the SunRISe-4 trial by Andrea Necchi and colleagues.1 This study assessed the efficacy and safety of neoadjuvant TAR-200 plus cetrelimab in patients with muscle-invasive bladder cancer who were ineligible for or declined cisplatin-based chemotherapy.1 The authors reported a 42% pathological complete response rate with manageable toxicity, underscoring the potential to combine intravesical gemcitabine delivery with PD-1 blockade. Although these findings expand treatment options for cisplatin-ineligible patients, we highlight two points to enhance interpretability and clinical translation.